[Music] We do a lot of good research in our universities. um and uh it is widely published also but what happens is that usually we are not able to commercialize that because it's a very long journey and we don't choose to move on to that journey um our research is uh you know taken up by the west it's usually open source and they make money but I chose not to publish my research when I was doing my PhD. I chose to get patents on the technologies invented and I decided to keep moving on and develop it into ...

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmaciesOnce-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the goMolluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURH ...

6月30日，深交所正式受理了惠科股份有限公司（简称：惠科股份）主板IPO申请。 在智能显示终端业务方面，公司拥有重庆金扬、合肥金扬、广西智显、宜昌惠科、东莞惠智和越南惠科 等多座显示终端生产基地，主要产品包括电视、显示器、电子纸、一体机、广告机、智能会议机、智慧 健身镜、智能穿戴设备等显示终端。依托在半导体显示面板与显示终端领域的核心资源和技术积累，公 司持续深化IT及智慧物联显示终端领域布局，进一步丰富产品线，为智慧教育、智慧办公、智慧交通、 智慧安防和智慧医疗等各应用场景提供各类显示终端产品及服务，有力推动业务的持续增长。 目前，惠科股份已与众多全球知名品牌客户建立了深度的合作关系，包括三星、LG、小米、海信、 TCL、海尔、联想惠普、戴尔、宏碁、VESTEL、创维、长虹、冠捷、微星科技等极具影响力的全球知 名品牌。 2022-2024年，惠科股份实现营业收入分别为271.34亿元、357.97亿元、403.1亿元；对应的净利润分别 为-14.28亿元、25.66亿元、33.39亿元。 此次IPO，惠科股份拟募资85亿元，投建于长沙新型 OLED 研发升级项目、长沙 Oxide 研发及产业化项 目、绵阳 ...

Financial Data and Key Metrics Changes - For the fiscal year ended 03/31/2025, the company reported a 220% increase in revenue to $3,700,000 compared to $1,200,000 for the same period last year [5][19] - The company anticipates revenue of at least $1,700,000 for the quarter ending 06/30/2025, representing greater than 45% sequential quarterly growth and greater than 145% year-over-year growth [6] - Revenue guidance for the full fiscal year ending 03/31/2026 is projected to be between $12,000,000 and $16,000,000 [6][21] - The net loss attributed to common stockholders for the fiscal year was $46,600,000, or a loss of $0.69 per share, compared to a net loss of $60,200,000, or a loss of $1.82 per share, for the previous fiscal year [21] Business Line Data and Key Metrics Changes - The commercial team secured three new hospital contracts and renewed three contracts during the fourth quarter [8] - The company has established a solid customer base across key target regions in the US, with 45 hospitals either installed or using the LungFit system [68] Market Data and Key Metrics Changes - The company has ramped up its commercial program across Europe, Southeast Asia, and the Middle East, securing key regulatory approvals and signing distribution agreements covering over 2,000,000,000 lives [11] - Initial shipments of LungFit PH to international customers have begun, with expectations for meaningful contributions to financial results starting in the latter half of fiscal 2026 [12] Company Strategy and Development Direction - The company aims to make LungFit PH the market leader in the nitric oxide market, overcoming barriers to entry and enhancing customer confidence through increased usage [7] - The introduction of LungFit PH2, a next-generation system, is expected to significantly impact market share and logistics within hospitals [10] - The company is focused on cost reduction efforts, having reduced operating expenses from over $17,000,000 to just above $7,000,000 in the current quarter, translating to a 58% reduction [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets for the upcoming quarter and fiscal year, citing strong customer interest and flexibility in contract structures [66] - The company is optimistic about the potential for international growth, although it acknowledges the longer tender processes outside the US [31][59] Other Important Information - The company received orphan drug designation from the FDA for its lead investigational therapy BA102, which is being developed for the treatment of Phelan McDermott syndrome [13] - The company announced the appointment of Bob Goodman to the board of directors, bringing extensive commercial leadership experience [16] Q&A Session Summary Question: Is the approval of LungFit 2.0 included in the fiscal year 2026 guidance? - Management confirmed that the fiscal year 2026 guidance does not include the second-generation system [28] Question: What are the dynamics of international contracts and usage compared to US hospitals? - Management indicated that initial shipments are for demonstration purposes, and the tender process outside the US takes longer [31] Question: What is the expected timeline for FDA approval of LungFit 2.0? - Management refrained from providing a specific timeline, noting the current upheaval at the FDA [40] Question: What factors could lead to achieving the higher end of the revenue guidance range? - Management mentioned that securing large contracts and regulatory approvals could significantly impact revenue [42] Question: How is the company addressing potential geopolitical impacts on supply and sales? - Management stated that the majority of manufacturing is in the US, and geopolitical issues have minimal impact on costs [53] Question: How does LungFit 2.0 expand the market? - Management noted that the new system would allow access to every hospital wanting to use nitric oxide, significantly increasing market reach [82]

Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe, Australia, and the ...

Core Viewpoint - Inflection Resources Ltd. has entered into a definitive agreement to acquire a 100% interest in a portfolio of Australian copper-gold exploration projects from Newmont Corporation, which includes the Tennant East and Bell River projects, indicating a strategic expansion in high-potential mineral exploration [1][3][8]. Group 1: Project Details - The Bell River project spans approximately 115 km² and is located in the Macquarie Arc, known for its rich porphyry copper-gold deposits, situated 65 km north of Newmont's Cadia mine [5][8]. - Significant geological features at Bell River include advanced argillic alteration zones and high gold values of up to 40.8 g/t, with copper content reaching 1% in surface rock samples [6][7]. - The Tennant East project covers around 4,200 km² and consists of twelve exploration licenses, targeting Iron Oxide Copper Gold (IOCG) mineralization with minimal prior exploration [13][15]. Group 2: Acquisition Terms - For the Bell River project, Inflection will issue 1,000,000 common shares to Newmont and make a one-time payment of AUD$2.5 million upon completion of a JORC or NI43-101 compliant Pre-Feasibility Study, plus AUD$5.0 million upon the start of commercial production [21]. - The Tennant East project acquisition involves issuing 250,000 common shares and reimbursing Newmont for tenement renewal fees, with Newmont retaining a 1.5% net smelter return (NSR) royalty [22]. Group 3: Exploration Strategy - Inflection's exploration strategy will focus on systematic reviews of previous exploration data, geological interpretation, and the integration of geological, geochemical, and geophysical data to identify potential mineralization [20]. - The company aims to explore the newly acquired projects in parallel with its existing exploration programs funded by AngloGold Ashanti, leveraging its systematic exploration approach [3][8].

Core Viewpoint - Inflection Resources Ltd. has entered into a definitive agreement to acquire a 100% interest in a portfolio of Australian copper-gold exploration projects from Newmont Corporation, which includes the Tennant East and Bell River projects, indicating a strategic expansion in high-potential mineral exploration [1][3][8]. Group 1: Project Details - The Bell River project, covering approximately 115 km², is located in New South Wales and is situated near significant mining operations, including Newmont's Cadia mine [5][8]. - The geological composition of the Bell River tenement includes calc-alkaline Mid-Ordovician Fairbridge Volcanics, which host advanced argillic alteration zones interpreted as relic porphyry-related lithocaps [6][10]. - The Tennant East project consists of twelve exploration licenses totaling around 4,200 km² in the Northern Territory, which are considered highly prospective for Iron Oxide Copper Gold (IOCG) targets [12][8]. Group 2: Exploration Potential - Inflection's systematic exploration strategy will leverage previous exploration data and geological interpretations to identify potential copper-gold mineralization at depth, particularly in areas with minimal prior drilling [10][19]. - The Bell River project is noted for its significant zones of advanced argillic alteration and outcropping lithocaps, which are indicative of preserved porphyry systems [9][10]. - The Tennant East project has shown promising early results from cursory exploration, including geochemical footprints consistent with IOCG mineralization [15][12]. Group 3: Agreement Terms - For the Bell River project, Inflection will issue 1,000,000 common shares to Newmont and make a one-time payment of AUD$2.5 million upon completion of a compliant Pre-Feasibility Study, along with a AUD$5 million payment upon the start of commercial production [20]. - The Tennant East project acquisition involves issuing 250,000 common shares and reimbursing Newmont for tenement renewal fees, with Newmont retaining a 1.5% net smelter return (NSR) royalty [21]. - The transactions are expected to close in several weeks, pending the transfer of exploration licenses and share issuance [22].

Watch LIVE as JAXA launches GOSAT-GW (Greenhouse Gases Observing Satellite Greenhouse gases and Water Cycle), formerly known as GOSAT 3; JAXA's next-generation satellite to monitor the greenhouse gases like carbon dioxide in the Earth's atmosphere to Sun-Synchronous Orbit from LA-Y1 at Tanegashima Space Center in Japan Join our community Discord! https://discord.com/invite/xCm9UpDPE4 This coverage is made possible by our amazing community! Consider becoming a The Launch Pad Member and go behind the scenes w ...

CALGARY, Alberta, May 21, 2025 (GLOBE NEWSWIRE) -- Questor Technology Inc. ("Questor" or the "Company") (TSX-V: QST) announced today its financial and operating results for the first quarter ended March 31, 2025. Questor's unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the quarter ended March 31, 2025, are available on the Company's website at www.questortech.com/investor-relations and at www.sedarplus.ca. Unless otherwise noted, all financial figures are ...

Core Insights - Beyond Air, Inc. is set to report its financial results for the fiscal fourth quarter and full year ending March 31, 2025, on June 17, 2025 [1] - The company specializes in medical devices and biopharmaceuticals, focusing on nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [3][4] Financial Reporting - The financial results will be discussed in a conference call and webcast scheduled for June 17, 2025, at 4:30 PM Eastern Time [1][2] - The conference call can be accessed via domestic and international phone lines, with a conference ID provided for participants [2] Company Overview - Beyond Air has received FDA approval and CE Mark for its LungFit® PH system, aimed at treating neonates with hypoxic respiratory failure [3] - The company is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [3] - A partnership with The Hebrew University of Jerusalem is focused on pre-clinical programs for autism spectrum disorder and other neurological disorders [4] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [4]